• Explore /
  • Poster
  • / A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.

A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.

Abstract Poster

Authors

null

Jean-Luc Van Laethem

Hôpital Universitaire Erasme, Brussels, Belgium

Jean-Luc Van Laethem , Volker Heinemann , Uwe Marc Martens , Jacek Jassem , Patrick Michl , Marc Peeters , Colin D. Weekes , Raphael Maréchal , Jens Stieler , Marius Giurescu , Prabhu Rajagopalan , Vittorio Luigi Garosi , Hanno Riess

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01251640

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4050)

DOI

10.1200/jco.2012.30.15_suppl.4050

Abstract #

4050

Poster Bd #

42A

Abstract Disclosures

Similar Posters

First Author: Richard Tuli

First Author: Eric Van Cutsem

First Author: Jean-Luc Van Laethem

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).

First Author: Rishi Surana